Home › Funds › TCG Crossover Management, LLC › SLN
TCG Crossover Management, LLC position in SLN
SILENCE THERAPEUTICS PLC · Health Care
TCG Crossover Management, LLC reported holding 3,033,560 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q2 2026 13F filing — a position valued at US$33.3M, representing 0.80% of its reported portfolio and ranking #32 among its reported holdings. TCG Crossover Management, LLC has disclosed SLN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's SLN position evolved
TCG Crossover Management, LLC first disclosed a stake in SLN in Q3 2023 at 2,104,875 shares (US$20.7M). The position peaked in Q1 2024 at 3,295,350 shares, worth US$71.2M. Across 12 filings, TCG Crossover Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 3,033,560 shares valued at US$33.3M. Notable position changes include a 57% increase in Q1 2024 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.10M | $20.67M | New |
| Q4 2023 | 2.10M | $36.56M | Hold |
| Q1 2024 | 3.30M | $71.18M | Add |
| Q2 2024 | 3.30M | $62.61M | Hold |
| Q3 2024 | 3.03M | $55.15M | Reduce |
| Q4 2024 | 3.03M | $20.87M | Hold |
| Q1 2025 | 3.03M | $8.55M | Hold |
| Q2 2025 | 3.03M | $17.59M | Hold |
| Q3 2025 | 3.03M | $15.74M | Hold |
| Q4 2025 | 3.03M | $18.44M | Hold |
| Q1 2026 | 3.03M | $15.99M | Hold |
| Q2 2026 | 3.03M | $33.31M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLN and 13F data
SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 35 other funds we track also report a position in SLN — the largest reported positions include Siren, L.L.C. (US$36.4M), Redmile Group, LLC (US$23.8M), Nantahala Capital Management, LLC (US$14.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLN
- Siren, L.L.C. 3.31M sh · $36.36M · Q2 2026
- Redmile Group, LLC 2.16M sh · $23.77M · Q2 2026
- Nantahala Capital Management, LLC 1.35M sh · $14.79M · Q2 2026
- Nextech Invest Ltd. 952.40K sh · $10.46M · Q2 2026
- 5AM Venture Management, LLC 476.20K sh · $5.23M · Q2 2026
- GREAT POINT PARTNERS LLC 450.00K sh · $4.94M · Q2 2026
- Tetragon Partners GP Ltd 300.00K sh · $3.29M · Q2 2026
- Ishara Investments LP 55.35K sh · $2.43M · Q2 2026
- Propel Bio Management, LLC 191.73K sh · $2.11M · Q2 2026
- M28 Capital Management LP 101.20K sh · $1.11M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held SLN?
TCG Crossover Management, LLC has disclosed SLN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is TCG Crossover Management, LLC's current position in SLN?
As of Q2 2026, TCG Crossover Management, LLC holds 3.03M shares of SLN (SILENCE THERAPEUTICS PLC), valued at $33.31M, representing 0.80% of its reported portfolio and ranking #32.
Has TCG Crossover Management, LLC been buying or selling SLN?
In the latest 13F filing (Q2 2026), TCG Crossover Management, LLC held unchanged its position in SLN. The position peaked in Q1 2024 at 3.30M shares.
Which other funds hold SLN?
Other major institutional holders of SLN include Siren, L.L.C., Redmile Group, LLC, Nantahala Capital Management, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.